Seven Fleet Capital Management LP Takes Position in Compass Therapeutics, Inc. $CMPX

Seven Fleet Capital Management LP bought a new stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 233,066 shares of the company’s stock, valued at approximately $510,415. Seven Fleet Capital Management LP owned approximately 0.13% of Compass Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Artia Global Partners LP bought a new position in Compass Therapeutics in the 2nd quarter valued at $839,000. Bank of America Corp DE purchased a new stake in shares of Compass Therapeutics during the second quarter worth $1,242,000. Jupiter Topco LLC bought a new stake in Compass Therapeutics in the second quarter valued at approximately $121,000. ADAR1 Capital Management LLC purchased a new position in shares of Compass Therapeutics in the 2nd quarter worth about $267,000. Finally, Canada Pension Plan Investment Board purchased a new position in shares of Compass Therapeutics in the second quarter valued at about $352,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Stock Down 4.8%

NASDAQ:CMPX traded down $0.12 during trading hours on Friday, reaching $2.40. 2,562,744 shares of the company’s stock were exchanged, compared to its average volume of 4,559,968. The firm has a market capitalization of $432.21 million, a price-to-earnings ratio of -6.00 and a beta of 0.92. The company has a 50-day moving average of $2.18 and a 200 day moving average of $3.47. Compass Therapeutics, Inc. has a 1-year low of $1.61 and a 1-year high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Research analysts forecast that Compass Therapeutics, Inc. will post -0.47 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on CMPX shares. Wall Street Zen cut shares of Compass Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Stifel Nicolaus set a $6.00 price objective on Compass Therapeutics in a research note on Monday, June 1st. LADENBURG THALM/SH SH assumed coverage on Compass Therapeutics in a research note on Wednesday, July 1st. They set a “buy” rating and a $5.00 price objective for the company. Citigroup reiterated a “market outperform” rating on shares of Compass Therapeutics in a research note on Thursday, June 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Compass Therapeutics has an average rating of “Moderate Buy” and an average target price of $11.77.

Compass Therapeutics Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.